Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS101 vs Dupixent in Healthy Male Adults
NCT07411755Phase 1Completed
- Sponsor
- Genscript ProBio
- Start
- Mar 2026
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GS101 in atopic dermatitis (AD) (3 arms), sponsored by Genscript ProBio. Primary endpoint: Pharmacokinetics. Started Mar 2026; status: completed.
02
Drugs
GS101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07411755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411755.